<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Pharma News: Drug Approvals, Clinical Trials &amp; Updates</title>
	<atom:link href="https://www.pharmaadvancement.com/pharma-news/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.pharmaadvancement.com</link>
	<description>Latest Pharmaceutical News</description>
	<lastBuildDate>Thu, 15 Oct 2026 07:45:13 +0000</lastBuildDate>
	<language>en-GB</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.10</generator>

<image>
	<url>https://www.pharmaadvancement.com/wp-content/uploads/2025/12/cropped-Pharmaa-Dvancement-Fevicon-32x32.jpg</url>
	<title>Pharma News: Drug Approvals, Clinical Trials &amp; Updates</title>
	<link>https://www.pharmaadvancement.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>FDA Targets Rare Disease Under New Framework Initiative</title>
		<link>https://www.pharmaadvancement.com/pharma-news/fda-targets-rare-disease-under-new-framework-initiative/</link>
		
		<dc:creator><![CDATA[API PA]]></dc:creator>
		<pubDate>Thu, 15 Oct 2026 07:43:28 +0000</pubDate>
				<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.pharmaadvancement.com/uncategorised/fda-targets-rare-disease-under-new-framework-initiative/</guid>

					<description><![CDATA[<p>The U.S. Food and Drug Administration (FDA), part of the U.S. Department of Health and Human Services (HHS), has announced the Rare Disease Framework Initiative to reshape the development and regulatory review of drugs and biologics for rare diseases. The initiative, detailed in a new white paper, aims to establish an optimized, fit-for-purpose framework that [&#8230;]</p>
The post <a href="https://www.pharmaadvancement.com/pharma-news/fda-targets-rare-disease-under-new-framework-initiative/">FDA Targets Rare Disease Under New Framework Initiative</a> appeared first on <a href="https://www.pharmaadvancement.com">Pharma Advancement</a>.]]></description>
										<content:encoded><![CDATA[<p>The U.S. Food and Drug Administration (FDA), part of the U.S. Department of Health and Human Services (HHS), has announced the Rare Disease Framework Initiative to reshape the development and regulatory review of drugs and biologics for <a href="https://www.pharmaadvancement.com/market-moves/optical-genome-mapping-boosting-rare-disease-diagnostics/" target="_blank" rel="noopener">rare diseases</a>. The initiative, detailed in a new white paper, aims to establish an optimized, fit-for-purpose framework that accounts for the specific challenges associated with developing treatments for rare conditions.</p>
<p>The proposed approach will consider the characteristics of individual diseases, patient needs, product types and the evidence that can realistically be generated from small patient populations. Through the Rare Disease Framework Initiative, the <a href="https://www.pharmaadvancement.com/pharma-news/fda-expands-breast-cancer-treatment-through-etcamah-approval/" target="_blank" rel="noopener">FDA</a> intends to develop a regulatory approach that better reflects the circumstances of rare disease drug development while addressing the needs of patients and families. To gather feedback from patients, disease advocates, industry representatives and other stakeholders, the agency will hold a public meeting on 28th October 2026 at the FDA’s White Oak campus. The Reagan-Udall Foundation for the FDA will facilitate the meeting.</p>
<div>
<div>
<h3><strong>FDA Highlights Patient Needs and Regulatory Flexibility</strong></h3>
<p>“Americans with rare diseases cannot afford a regulatory system that treats every condition the same,” said HHS Secretary Robert F. Kennedy, Jr.</p>
<p>“Under President Trump, FDA is rethinking rare disease drug development by putting patients at the center and matching regulatory requirements to the realities of small patient populations. We will remove unnecessary barriers, embrace cutting-edge science, and accelerate promising treatments while upholding FDA’s rigorous standards,” he added.</p>
<p>“Patients and families living with rare diseases have few or no approved treatment options, and the burden of uncertainty can extend across every part of their lives,” said Acting FDA Commissioner Kyle Diamantas, J.D.</p>
<h3><strong>Six Priorities for Improving Rare Disease Treatment Development</strong></h3>
<p>The FDA has previously introduced regulatory flexibility and targeted programs to encourage innovation in developing drugs and biologics for rare diseases, resulting in meaningful advances for patients and families. However, with only 5% or so of rare conditions having an FDA-approved treatment, the agency recognizes the need for additional measures to accelerate the availability of safe and effective therapies. Under the Rare Disease Framework Initiative, the FDA has identified six priorities:</p>
<ul>
<li>Providing greater clarity, consistency and predictability in regulatory decisions through tailored guidance and transparent communication</li>
<li>Incorporating the patient’s voice early and at clearly defined milestones throughout drug development and review</li>
<li>Making greater use of external expertise to customize regulatory assessments</li>
<li>Developing shared resources, robust training and institutional knowledge for rare disease drug development and review</li>
<li>Adopting risk-based approaches, particularly for chemistry, manufacturing, and controls review and pre-approval inspections</li>
<li>Promoting cutting-edge science, novel methods and innovative statistical approaches in rare disease drug development</li>
</ul>
<p>The initiative is led by the FDA’s Rare Disease Innovation Hub in partnership with the Office of the Commissioner, the Center for Biologics Evaluation and Research, and the Center for Drug Evaluation and Research.</p>
</div>
</div>The post <a href="https://www.pharmaadvancement.com/pharma-news/fda-targets-rare-disease-under-new-framework-initiative/">FDA Targets Rare Disease Under New Framework Initiative</a> appeared first on <a href="https://www.pharmaadvancement.com">Pharma Advancement</a>.]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Egypt, China to Jointly Boost Pharmaceutical Manufacturing</title>
		<link>https://www.pharmaadvancement.com/manufacturing/egypt-china-to-jointly-boost-pharmaceutical-manufacturing/</link>
		
		<dc:creator><![CDATA[API PA]]></dc:creator>
		<pubDate>Thu, 01 Oct 2026 10:33:21 +0000</pubDate>
				<category><![CDATA[Manufacturing]]></category>
		<category><![CDATA[Middle East and South Asia]]></category>
		<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.pharmaadvancement.com/uncategorised/egypt-china-to-jointly-boost-pharmaceutical-manufacturing/</guid>

					<description><![CDATA[<p>Egypt has initiated discussions aimed at deepening regulatory cooperation with China and broadening partnerships in pharmaceutical manufacturing, vaccines, and technology transfer initiatives. The Egyptian Drug Authority (EDA) announced these developments following high-level diplomatic engagement between regulatory officials from both nations. Strategic Meeting Between Regulatory Bodies A significant meeting took place between Ali El-Ghamrawy, Chairperson of [&#8230;]</p>
The post <a href="https://www.pharmaadvancement.com/manufacturing/egypt-china-to-jointly-boost-pharmaceutical-manufacturing/">Egypt, China to Jointly Boost Pharmaceutical Manufacturing</a> appeared first on <a href="https://www.pharmaadvancement.com">Pharma Advancement</a>.]]></description>
										<content:encoded><![CDATA[<p style="user-select: auto !important;">Egypt has initiated discussions aimed at deepening regulatory cooperation with China and broadening partnerships in pharmaceutical manufacturing, vaccines, and technology transfer initiatives. The Egyptian Drug Authority (EDA) announced these developments following high-level diplomatic engagement between regulatory officials from both nations.</p>
<h3 style="user-select: auto !important;"><strong style="user-select: auto !important;">Strategic Meeting Between Regulatory Bodies</strong></h3>
<p style="user-select: auto !important;">A significant meeting took place between Ali El-Ghamrawy, Chairperson of the Egyptian Drug Authority, and Yang Xing, Deputy Commissioner of China&#8217;s National Medical Products Administration (NMPA). The engagement was facilitated by Khaled Nazmy, Egypt&#8217;s Ambassador to China, alongside representatives from the Chinese regulatory body.</p>
<div style="user-select: auto !important;">
<h3 style="user-select: auto !important;"><strong style="user-select: auto !important;">Focus Areas of the Regulatory Partnership</strong></h3>
<p style="user-select: auto !important;">The dialogue between Egyptian and Chinese officials centered on several critical dimensions of pharmaceutical manufacturing cooperation. Both parties emphasized the importance of exchanging regulatory expertise and identifying emerging opportunities within the pharmaceutical sector.</p>
</div>
<h3 style="user-select: auto !important;"><strong style="user-select: auto !important;">Egypt&#8217;s Manufacturing and Regulatory Capabilities</strong></h3>
<p style="user-select: auto !important;">El-Ghamrawy presented Egypt&#8217;s substantial strengths in pharmaceutical manufacturing and vaccine production capabilities. He also emphasized the recent developments in the country&#8217;s regulatory and manufacturing frameworks that have strengthened Egypt&#8217;s  competitiveness within the global pharmaceutical sector. These advancements create a solid foundation for pharmaceutical manufacturing cooperation with international partners, particularly nations with advanced technological expertise like China.</p>
<div id="model-response-message-contentr_e497d3a3764b9b64" class="markdown markdown-main-panel md-content enable-luminous-fast-follows enable-updated-hr-color stronger tutor-markdown-rendering" dir="ltr" style="user-select: auto !important;" aria-busy="false" aria-live="polite">
<div style="user-select: auto !important;">The head of the EDA noted that recent advancements establish a strong base for broader global partnerships, facilitating the exchange of technical knowledge and strengthening organizational frameworks. Ultimately, these efforts aim to ensure a stable and reliable supply chain for medicines and immunizations.</div>
<div style="user-select: auto !important;"></div>
</div>
<h3 style="user-select: auto !important;"><strong style="user-select: auto !important;">Areas of Collaborative Development</strong></h3>
<p style="user-select: auto !important;">During their discussions, officials from both nations explored joint ventures in drug production, the sharing of regulatory protocols, and further technological integration. The chairperson specifically emphasized that combining China&#8217;s high-tech innovations and specialized skills with Egypt&#8217;s robust production infrastructure and legal guidelines will significantly advance the pharmaceutical sector and open up fresh investment avenues.</p>
<p style="user-select: auto !important;">Additionally, discussions addressed mechanisms for strengthening institutional coordination between the Egyptian Drug Authority and China&#8217;s National Medical Products Administration. The two sides also explored potential frameworks for joint cooperation and established pathways for partnerships between companies operating in both markets.</p>
<h3 style="user-select: auto !important;"><strong style="user-select: auto !important;">Broader Strategic Context</strong></h3>
<p style="user-select: auto !important;">This engagement as part of a comprehensive strategy to expand cooperation with international regulatory authorities worldwide. Through such partnerships, Egypt seeks to exchange expertise and best practices, strengthen regulatory and manufacturing capabilities, and support technology transfer initiatives.</p>
<div id="model-response-message-contentr_5c135bc4912bcad3" class="markdown markdown-main-panel md-content enable-luminous-fast-follows enable-updated-hr-color stronger tutor-markdown-rendering" dir="ltr" style="user-select: auto !important;" aria-busy="false" aria-live="polite">
<div style="user-select: auto !important;">According to the agency, these initiatives are designed to bolster the nation&#8217;s medical resilience while cementing its status as a key production center for the region and a strategic entry point into the broader African market.</div>
</div>The post <a href="https://www.pharmaadvancement.com/manufacturing/egypt-china-to-jointly-boost-pharmaceutical-manufacturing/">Egypt, China to Jointly Boost Pharmaceutical Manufacturing</a> appeared first on <a href="https://www.pharmaadvancement.com">Pharma Advancement</a>.]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>EDA, Swissmedic Boost Pharmaceutical Regulatory Partnership</title>
		<link>https://www.pharmaadvancement.com/pharma-news/eda-swissmedic-boost-pharmaceutical-regulatory-partnership/</link>
		
		<dc:creator><![CDATA[API PA]]></dc:creator>
		<pubDate>Mon, 21 Sep 2026 10:54:18 +0000</pubDate>
				<category><![CDATA[Manufacturing]]></category>
		<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.pharmaadvancement.com/uncategorised/eda-swissmedic-boost-pharmaceutical-regulatory-partnership/</guid>

					<description><![CDATA[<p>The Egyptian Drug Authority (EDA), under the leadership of Dr. Ali El Ghamrawy, held a virtual strategic meeting with Swissmedic, the Swiss Agency for Therapeutic Products, 19th September 2026. Led by Ms. Vincenza Trivigno, Chief Executive Officer of Swissmedic, the discussions centered on deepening the pharmaceutical regulatory partnership and advancing collaborative efforts in critical areas [&#8230;]</p>
The post <a href="https://www.pharmaadvancement.com/pharma-news/eda-swissmedic-boost-pharmaceutical-regulatory-partnership/">EDA, Swissmedic Boost Pharmaceutical Regulatory Partnership</a> appeared first on <a href="https://www.pharmaadvancement.com">Pharma Advancement</a>.]]></description>
										<content:encoded><![CDATA[<p style="user-select: auto !important;">The Egyptian Drug Authority (EDA), under the leadership of Dr. Ali El Ghamrawy, held a virtual strategic meeting with Swissmedic, the Swiss Agency for Therapeutic Products, 19th September 2026. Led by Ms. Vincenza Trivigno, Chief Executive Officer of Swissmedic, the discussions centered on deepening the pharmaceutical regulatory partnership and advancing collaborative efforts in critical areas affecting Egypt&#8217;s drug approval and manufacturing frameworks.</p>
<h3 style="user-select: auto !important;"><strong style="user-select: auto !important;">Focus Areas of the Pharmaceutical Regulatory Partnership</strong></h3>
<p style="user-select: auto !important;">The pharmaceutical regulatory partnership agenda encompassed several key priorities designed to elevate Egypt&#8217;s regulatory infrastructure. Primary discussion points included strengthening Good Manufacturing Practices (GMP) standards, accessing specialized technical expertise, and implementing comprehensive capacity building programs. Both organizations emphasized the importance of aligning Egypt&#8217;s regulatory approaches with the latest international pharmaceutical regulatory standards and best practices established globally.</p>
<h3 style="user-select: auto !important;"><strong style="user-select: auto !important;">Strategic Commitment to Regulatory Excellence</strong></h3>
<p style="user-select: auto !important;">Dr. Ali El Ghamrawy commended the existing depth of cooperation between the EDA and Swissmedic, recognizing Switzerland&#8217;s advanced regulatory expertise as instrumental for enhancing Egypt&#8217;s institutional capabilities.</p>
<p style="user-select: auto !important;">Ms. Vincenza Trivigno, representing Swissmedic, reciprocated the commitment by acknowledging the value of the pharmaceutical regulatory partnership and expressing confidence in further developing areas of mutual cooperation. She highlighted how the exchange of regulatory best practices supports the development of technical and institutional capacities.</p>
<h3 style="user-select: auto !important;"><strong style="user-select: auto !important;">Implementation of Practical Training and Knowledge Exchange</strong></h3>
<p style="user-select: auto !important;">Both organizations discussed concrete mechanisms for executing practical training programs and facilitating technical knowledge exchange initiatives. These collaborative efforts aim to strengthen regulatory practices throughout Egypt&#8217;s pharmaceutical sector while ensuring continued alignment with internationally recognized pharmaceutical regulatory standards. The training frameworks will specifically address Good Manufacturing Practices (GMP) compliance and other essential areas in pharmaceutical regulation.</p>
<p style="user-select: auto !important;">The pharmaceutical regulatory partnership represents a significant step in the EDA&#8217;s broader strategy to engage with leading international regulatory authorities. This engagement supports the Egyptian Drug Authority&#8217;s vision of maintaining institutional excellence and ensuring that Egypt&#8217;s pharmaceutical manufacturing sector operates under the most rigorous standards. Such cooperation directly benefits public health outcomes by guaranteeing the quality, safety, and efficacy of pharmaceutical products and vaccines distributed within Egypt and across regional markets.</p>
<p style="user-select: auto !important;">This pharmaceutical regulatory partnership underscores the Egyptian Drug Authority’s ongoing commitment to regulatory excellence, driven by active collaboration with global peers and strategic alliances that enhance institutional capacity.</p>The post <a href="https://www.pharmaadvancement.com/pharma-news/eda-swissmedic-boost-pharmaceutical-regulatory-partnership/">EDA, Swissmedic Boost Pharmaceutical Regulatory Partnership</a> appeared first on <a href="https://www.pharmaadvancement.com">Pharma Advancement</a>.]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Sanofi, VNVC to Make Next-Generation Vaccines in Vietnam</title>
		<link>https://www.pharmaadvancement.com/pharma-news/sanofi-vnvc-to-make-next-generation-vaccines-in-vietnam/</link>
		
		<dc:creator><![CDATA[API PA]]></dc:creator>
		<pubDate>Fri, 11 Sep 2026 12:27:40 +0000</pubDate>
				<category><![CDATA[Manufacturing]]></category>
		<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.pharmaadvancement.com/uncategorised/sanofi-vnvc-to-make-next-generation-vaccines-in-vietnam/</guid>

					<description><![CDATA[<p>In a landmark cross-border healthcare agreement presented directly to Vietnam&#8217;s General Secretary and President To Lam and French President Emmanuel Macron, French pharmaceutical giant Sanofi and Vietnam Vaccine Joint Stock Company (VNVC) announced plans to manufacture three next-generation vaccines in Vietnam. Formalized in Paris during the Vietnam-France Business Forum, a gathering where both heads of [&#8230;]</p>
The post <a href="https://www.pharmaadvancement.com/pharma-news/sanofi-vnvc-to-make-next-generation-vaccines-in-vietnam/">Sanofi, VNVC to Make Next-Generation Vaccines in Vietnam</a> appeared first on <a href="https://www.pharmaadvancement.com">Pharma Advancement</a>.]]></description>
										<content:encoded><![CDATA[<div id="model-response-message-contentr_b11d2672fc172ad4" class="markdown markdown-main-panel md-content enable-luminous-fast-follows enable-updated-hr-color stronger tutor-markdown-rendering" dir="ltr" style="user-select: auto !important;" aria-busy="false" aria-live="polite">
<div style="user-select: auto !important;">In a landmark cross-border healthcare agreement presented directly to Vietnam&#8217;s General Secretary and President To Lam and French President Emmanuel Macron, French pharmaceutical giant Sanofi and Vietnam Vaccine Joint Stock Company (VNVC) announced plans to manufacture three next-generation vaccines in Vietnam. Formalized in Paris during the Vietnam-France Business Forum, a gathering where both heads of state convened with corporate leaders to evaluate strategic cooperation across fields such as pharmaceuticals and healthcare, the two organizations exchanged a joint declaration in the presence of top French and Vietnamese officials. Under this pact, Vietnam will become the first country in Southeast Asia to manufacture three next-generation vaccines developed by France&#8217;s Sanofi under a new partnership with VNVC, prioritizing their production locally at VNVC&#8217;s Vaccine and Biologics Manufacturing Plant.</div>
<h3 style="user-select: auto !important;" data-path-to-node="6"><strong style="user-select: auto !important;">Product Portfolio, Timelines, and Regional Ambitions</strong></h3>
<div style="user-select: auto !important;">The initial manufacturing roster targets essential public health solutions that address substantial domestic demand across several age demographics by guarding against severe, potentially fatal infectious conditions. Specifically, the rollout focuses on an acellular pertussis-containing six-in-one vaccine, a seasonal influenza vaccine, and a meningococcal vaccine. Highlighting the milestone, Ngo Chi Dung, chairman and chief executive of VNVC, said the agreement would make Vietnam the first country in Southeast Asia capable of independently producing these next-generation vaccines.</div>
<div style="user-select: auto !important;"></div>
<div style="user-select: auto !important;">The current roadmap outlines the start of manufacturing operations in 2028, leading up to commercial distribution in 2029. Backed by initial output targeted at tens of millions of doses annually for local patients before scaling outward to regional territories and international supply networks, Dung noted his desire for continuous backing from both administrations to keep timelines on schedule and deliver superior immunizations at lower consumer costs.</div>
<h3 style="user-select: auto !important;" data-path-to-node="8"><strong style="user-select: auto !important;">Facility Footprint and Strategic Biotech Goals</strong></h3>
<div style="user-select: auto !important;">Production will center at VNVC&#8217;s Vaccine and Biologics Manufacturing Plant in Tay Ninh Province, an installation spanning more than 26,000 square metres that represents a phase-one outlay exceeding VND 2.5 trillion (USD 96 million) and carries a projected output potential of roughly 120 million vaccine doses per year. Emphasizing the broader strategic alignment, Stephen Alix, head of international markets for Sanofi&#8217;s vaccine division, commended Vietnam&#8217;s policy framework supporting innovation, science and technology, high-tech sectors, and overall healthcare resilience.</div>
<div style="user-select: auto !important;"></div>
<div style="user-select: auto !important;">&#8220;Through this project, Sanofi hopes to make a meaningful contribution to Vietnam&#8217;s national development goals and help build an increasingly modern biotechnology ecosystem in the country,&#8221; Alix said.</div>
<div style="user-select: auto !important;"></div>
<div style="user-select: auto !important;">Ultimately, this venture mirrors Vietnam&#8217;s overarching drive to lessen its dependence on overseas medical imports, fortify domestic immunization self-sufficiency, and establish a footprint as an advanced biotechnology and pharmaceutical manufacturing hub.</div>
</div>The post <a href="https://www.pharmaadvancement.com/pharma-news/sanofi-vnvc-to-make-next-generation-vaccines-in-vietnam/">Sanofi, VNVC to Make Next-Generation Vaccines in Vietnam</a> appeared first on <a href="https://www.pharmaadvancement.com">Pharma Advancement</a>.]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Tanzania, Algeria to Boost Pharmaceutical Manufacturing</title>
		<link>https://www.pharmaadvancement.com/pharma-news/tanzania-algeria-to-boost-pharmaceutical-manufacturing/</link>
		
		<dc:creator><![CDATA[API PA]]></dc:creator>
		<pubDate>Thu, 10 Sep 2026 11:34:06 +0000</pubDate>
				<category><![CDATA[Africa]]></category>
		<category><![CDATA[Manufacturing]]></category>
		<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.pharmaadvancement.com/uncategorised/tanzania-algeria-to-boost-pharmaceutical-manufacturing/</guid>

					<description><![CDATA[<p>Tanzania and Algeria are seeking to deepen cooperation in pharmaceutical manufacturing, with discussions focused on technology transfer, technical expertise and investment to strengthen Tanzania’s domestic production capacity and create opportunities to supply medicines and medical equipment to wider African markets. The latest development followed a meeting in Algiers between Tanzanian Ambassador to Algeria, Mobhare Matinyi, [&#8230;]</p>
The post <a href="https://www.pharmaadvancement.com/pharma-news/tanzania-algeria-to-boost-pharmaceutical-manufacturing/">Tanzania, Algeria to Boost Pharmaceutical Manufacturing</a> appeared first on <a href="https://www.pharmaadvancement.com">Pharma Advancement</a>.]]></description>
										<content:encoded><![CDATA[<p style="user-select: auto !important;">Tanzania and Algeria are seeking to deepen cooperation in pharmaceutical manufacturing, with discussions focused on technology transfer, technical expertise and investment to strengthen Tanzania’s domestic production capacity and create opportunities to supply medicines and medical equipment to wider African markets.</p>
<p style="user-select: auto !important;">The latest development followed a meeting in Algiers between Tanzanian Ambassador to Algeria, Mobhare Matinyi, and Algerian Minister of Pharmaceutical Industry, Dr. Wassim Kouidri, at the ministry’s headquarters. The two officials discussed ways to strengthen bilateral cooperation in the pharmaceutical industry, which Tanzania is increasingly viewing as both a public-health priority and an industrial opportunity. Expanding pharmaceutical manufacturing is closely connected to Tanzania’s efforts to reduce its dependence on imported medicines and establish a more secure domestic health-supply system.</p>
<p style="user-select: auto !important;">The Tanzania Medicines and Medical Devices Authority (TMDA) says the country remains heavily reliant on imports for medicines and medical devices, while the Government has set a target of achieving 80 percent local production of health products by 2030. Against this backdrop, Ambassador Matinyi told Dr. Kouidri that the Tanzanian Government has introduced special incentives to attract investment into the pharmaceutical industry. Five factories are already under construction, with further investments expected. According to TMDA, investors can access fiscal and non-fiscal incentives, including exemptions and reductions on selected taxes, duties and regulatory fees, expedited regulatory processes and other measures intended to facilitate investment.</p>
<p style="user-select: auto !important;">Tanzania also wants the expansion of production to serve markets beyond its domestic borders. Ambassador Matinyi highlighted the country’s strategic geographical position and growing manufacturing ambitions as foundations for an export-oriented pharmaceutical industry.</p>
<p style="user-select: auto !important;">“Our government is determined to turn Tanzania into an export hub for pharmaceutical and medical equipment in the eastern, central and southern African region, which has a population of approximately 350 million people,” said Ambassador Matinyi.</p>
<h3 style="user-select: auto !important;"><strong style="user-select: auto !important;">Algeria Offers Manufacturing and Regulatory Expertise</strong></h3>
<p style="user-select: auto !important;">The cooperation also provides Tanzania with an opportunity to draw on Algeria’s established pharmaceutical manufacturing capabilities. Algeria has developed one of Africa’s largest pharmaceutical manufacturing sectors. In 2025, Algerian authorities said the country had nearly 230 pharmaceutical factories out of 649 across the continent, representing more than one-third of Africa’s pharmaceutical manufacturing establishments.</p>
<p style="user-select: auto !important;">The World Health Organization has also highlighted Algeria’s progress, noting that the country has more than 230 manufacturers and produces about 82 percent of its pharmaceutical needs locally. This experience could help Tanzania develop capabilities extending beyond conventional trade, including industrial know-how, manufacturing processes, regulatory systems, professional training and technology transfer.</p>
<p style="user-select: auto !important;">Dr. Kouidri pledged Algeria’s support in helping Tanzania access critical expertise in pharmaceutical and medical equipment production.</p>
<p style="user-select: auto !important;">“Tanzania is certainly located in a strategic part of the continent of Africa, and Algeria is open to cooperate with it in the transfer of technology to ensure it achieves its industrial objectives,” said Dr. Kouidri.</p>
<p style="user-select: auto !important;">Technology transfer is particularly important because pharmaceutical manufacturing requires capabilities in formulation, quality control, Good Manufacturing Practices, validation, packaging and storage, as well as the production of active pharmaceutical ingredients and other higher-value inputs at more advanced stages.</p>
<p style="user-select: auto !important;">Regulatory cooperation is also emerging as an important part of the partnership. Ambassador Matinyi commended the Algerian National Pharmaceutical Products Authority (ANPP), which is expected to visit Tanzania later in October this year at the invitation of TMDA to explore technical cooperation.</p>
<p style="user-select: auto !important;">Tanzania became the first confirmed country in Africa to achieve WHO Maturity Level 3 under the Global Benchmarking Tool in 2018. WHO describes ML3 as a stable, well-functioning and integrated regulatory system, while ML4 represents the highest level, characterised by advanced performance and continuous improvement. Tanzania’s regulatory position supports its industrial ambitions, particularly as export-oriented production requires confidence that locally manufactured and imported medicines consistently meet standards of quality, safety and efficacy.</p>
<p style="user-select: auto !important;">The wider African regulatory landscape has also progressed, with WHO reporting in 2024 that Senegal and Rwanda had become the seventh and eighth African countries to attain ML3, joining Egypt, Ghana, Nigeria, South Africa, Tanzania and Zimbabwe. Tanzania has also pursued engagement with Algerian pharmaceutical manufacturers and the ANPP, identifying opportunities involving training, technology transfer, medical-device inspection and regulatory strengthening. Algerian manufacturers have expressed interest in registering products in Tanzania, supplying medicines to the Tanzanian market and potentially establishing manufacturing operations in the country, initially through activities such as secondary packaging and later moving towards full-scale production.</p>
<p style="user-select: auto !important;">The Medical Stores Department says Tanzania currently sources approximately 80 percent of medicines and 90 percent of medical supplies from various countries, while the Government is prioritising local procurement to encourage domestic manufacturing. Reducing this dependence will require sustained investment, competitive production, reliable electricity and water, access to finance, skilled human resources, research and development, efficient regulation and predictable government procurement.</p>
<p style="user-select: auto !important;">The Tanzania-Algeria discussions therefore bring together Tanzania’s market, strategic location, regulatory foundation and policy ambition with Algeria’s pharmaceutical manufacturing experience and technological expertise, potentially supporting Tanzania’s ambition to become a pharmaceutical manufacturing and export hub for the continent.</p>The post <a href="https://www.pharmaadvancement.com/pharma-news/tanzania-algeria-to-boost-pharmaceutical-manufacturing/">Tanzania, Algeria to Boost Pharmaceutical Manufacturing</a> appeared first on <a href="https://www.pharmaadvancement.com">Pharma Advancement</a>.]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>FDA Expands Breast Cancer Treatment through Etcamah Approval</title>
		<link>https://www.pharmaadvancement.com/pharma-news/fda-expands-breast-cancer-treatment-through-etcamah-approval/</link>
		
		<dc:creator><![CDATA[API PA]]></dc:creator>
		<pubDate>Tue, 08 Sep 2026 13:25:32 +0000</pubDate>
				<category><![CDATA[FDA Approvals]]></category>
		<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.pharmaadvancement.com/uncategorised/fda-expands-breast-cancer-treatment-through-etcamah-approval/</guid>

					<description><![CDATA[<p>The U.S. Food and Drug Administration (FDA) has expanded treatment options for adults with advanced breast cancer through the accelerated approval of Etcamah (camizestrant). The decision reflects the FDA’s continued focus on advancing medical innovation and making new treatments available to patients who need them. Etcamah has been approved for use with a CDK4/6 inhibitor [&#8230;]</p>
The post <a href="https://www.pharmaadvancement.com/pharma-news/fda-expands-breast-cancer-treatment-through-etcamah-approval/">FDA Expands Breast Cancer Treatment through Etcamah Approval</a> appeared first on <a href="https://www.pharmaadvancement.com">Pharma Advancement</a>.]]></description>
										<content:encoded><![CDATA[<p style="user-select: auto !important;">The U.S. Food and Drug Administration (FDA) has expanded treatment options for adults with advanced breast cancer through the accelerated approval of Etcamah (camizestrant). The decision reflects the FDA’s continued focus on advancing medical innovation and making new treatments available to patients who need them. Etcamah has been approved for use with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer. The treatment applies when an estrogen receptor-1 (<em style="user-select: auto !important;">ESR1</em>) mutation is detected during aromatase inhibitor and CDK 4/6 inhibitor therapy based on an FDA-authorized test.</p>
<p style="user-select: auto !important;"><em style="user-select: auto !important;">ESR1</em> mutations are resistance mutations that tumors may acquire while a patient is receiving an aromatase inhibitor, a type of endocrine therapy commonly used as a front-line treatment for locally advanced or metastatic breast cancer. At the time HR-positive metastatic breast cancer is diagnosed, fewer than 5 percent of patients have this tumor mutation. Following disease progression while receiving an aromatase inhibitor, however, nearly 40 percent of patients will have the mutation.</p>
<p style="user-select: auto !important;">&#8220;Women living with metastatic breast cancer face an uphill battle as their tumors continuously evolve to escape treatment. We owe them every weapon in our arsenal.&#8221; said Acting FDA Commissioner Kyle Diamantas, J.D.</p>
<p style="user-select: auto !important;">&#8220;Today’s approval delivers a win to these patients by granting them a targeted therapy designed specifically to overcome resistance, giving them more time before their disease progresses,&#8221; he added.</p>
<h3 style="user-select: auto !important;"><strong style="user-select: auto !important;">Accelerated Approval Requires Confirmatory Evidence</strong></h3>
<p style="user-select: auto !important;">Etcamah received accelerated approval based on progression-free survival, measuring how long patients remained without worsening disease from the point at which the resistance mutation was first identified in the blood. The FDA’s accelerated approval program permits earlier authorization of medicines intended for serious conditions that address an unmet medical need when approval is supported by surrogate or intermediate endpoints. Because it remains uncertain whether treating patients at the point of resistance mutation detection, instead of waiting for confirmed disease progression, provides a clinically meaningful benefit, the FDA has required confirmatory studies to establish and further describe the clinical benefit.</p>
<p style="user-select: auto !important;">“I commend both the FDA and the sponsor for their commitment to advancing cancer care and securing this accelerated approval,” said Angelo de Claro, M.D., director of the FDA’s Oncology Center of Excellence.</p>
<p style="user-select: auto !important;">ctDNA consists of small pieces of tumor DNA that are released into the bloodstream, providing an opportunity to detect resistance mutations at an earlier molecular stage. To support the identification of appropriate patients with breast cancer, the FDA also authorized the Guardant360 CDx assay as a companion diagnostic device for identifying patients with <em style="user-select: auto !important;">ESR1</em> mutations who may receive camizestrant.</p>
<h3 style="user-select: auto !important;"><strong style="user-select: auto !important;">Clinical Trial Shows Longer Progression-Free Survival</strong></h3>
<p style="user-select: auto !important;">The efficacy of Etcamah was assessed in a clinical trial comparing a switch to the oral tablet in combination with a CDK4/6 inhibitor against continued treatment with an aromatase inhibitor alongside a CDK4/6 inhibitor. The estimated median progression-free survival reached 16 months among patients receiving Etcamah and a CDK4/6 inhibitor. By comparison, the estimated median progression-free survival was 9.2 months in the aromatase inhibitor and CDK4/6 inhibitor arm. The results form the clinical basis for the expanded breast cancer treatment option under the FDA’s accelerated approval pathway.</p>The post <a href="https://www.pharmaadvancement.com/pharma-news/fda-expands-breast-cancer-treatment-through-etcamah-approval/">FDA Expands Breast Cancer Treatment through Etcamah Approval</a> appeared first on <a href="https://www.pharmaadvancement.com">Pharma Advancement</a>.]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>FDA Approves Zanvastro as First Alexander Disease Treatment</title>
		<link>https://www.pharmaadvancement.com/pharma-news/fda-approves-zanvastro-as-first-alexander-disease-treatment/</link>
		
		<dc:creator><![CDATA[API PA]]></dc:creator>
		<pubDate>Fri, 04 Sep 2026 06:55:04 +0000</pubDate>
				<category><![CDATA[FDA Approvals]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[  Biopharmaceutical Development]]></category>
		<category><![CDATA[FDA]]></category>
		<guid isPermaLink="false">https://www.pharmaadvancement.com/uncategorised/fda-approves-zanvastro-as-first-alexander-disease-treatment/</guid>

					<description><![CDATA[<p>The U.S. Food and Drug Administration has approved Zanvastro (zilganersen) injection for treating pediatric and adult patients with Alexander disease. The approval makes Zanvastro the first FDA-approved treatment for Alexander disease and the first therapy designed to directly target the protein buildup responsible for driving the disease. &#8220;For patients with Alexander disease and their families, [&#8230;]</p>
The post <a href="https://www.pharmaadvancement.com/pharma-news/fda-approves-zanvastro-as-first-alexander-disease-treatment/">FDA Approves Zanvastro as First Alexander Disease Treatment</a> appeared first on <a href="https://www.pharmaadvancement.com">Pharma Advancement</a>.]]></description>
										<content:encoded><![CDATA[<p style="user-select: auto !important;">The U.S. Food and Drug Administration has approved Zanvastro (zilganersen) injection for treating pediatric and adult patients with Alexander disease. The approval makes Zanvastro the first FDA-approved treatment for Alexander disease and the first therapy designed to directly target the protein buildup responsible for driving the disease.</p>
<p style="user-select: auto !important;">&#8220;For patients with Alexander disease and their families, there have been no approved treatment options — only supportive care while the disease progresses,&#8221; said Emily Freilich, M.D., Director of the Division of Neurology I in the FDA’s Center for Drug Evaluation and Research.</p>
<p style="user-select: auto !important;">&#8220;Today’s approval is a landmark moment for this community, offering the first therapy that addresses the underlying cause of this rare and serious disease,&#8221; she added.</p>
<p style="user-select: auto !important;">Alexander disease is a rare and progressive neurological disorder linked to mutations in the gene responsible for producing glial fibrillary acidic protein (GFAP). When the protein is abnormal, it builds up in the brain’s supportive cells and progressively damages the nervous system. The disease affects less than 1 in a million people and can result in serious, potentially life-threatening complications, including seizures, loss of developmental milestones, difficulty walking, muscle weakness, and increased pressure in the brain.</p>
<h3 style="user-select: auto !important;"><strong style="user-select: auto !important;">Zanvastro Targets Abnormal GFAP Protein</strong></h3>
<p style="user-select: auto !important;">Zanvastro belongs to a class of medicines known as antisense oligonucleotides. The treatment works by reducing the production of abnormal GFAP protein before it has the opportunity to accumulate and cause additional damage. The medicine is administered through an injection into the spinal canal once every three months, with the procedure performed by a trained healthcare professional.</p>
<p style="user-select: auto !important;">The safety and efficacy of Zanvastro were assessed through a multicenter, randomized, controlled clinical study (NCT04849741), which enrolled 49 pediatric and adult patients with Alexander disease who were 2 years of age and older. The evaluation also included an open-label substudy involving 4 patients less than 2 years of age. Given the rarity of Alexander disease and the broad age range across which it can occur, the FDA considered the available evidence to support an indication extending from infancy through adulthood.</p>
<h3 style="user-select: auto !important;"><strong style="user-select: auto !important;">Clinical Study Shows Improvement in Motor Function</strong></h3>
<p style="user-select: auto !important;">Among patients aged 5 years and older who had measurable walking difficulties at baseline, those receiving Zanvastro demonstrated significantly better walking speed at 61 weeks than patients who received no treatment. For children aged 2 to 4 years, walking speed was not considered a reliable way to measure progress. Instead, researchers used a broader assessment of motor skills covering standing, walking, running, and jumping. Children receiving Zanvastro improved on this assessment, while children in the control group declined.</p>
<p style="user-select: auto !important;">For patients under 2 years of age, direct clinical trial evidence was limited because of the rarity of the disease and the absence of a concurrent control group. Pharmacokinetic modeling indicated that drug levels among patients in this age group were expected to be similar to those observed in older children receiving the same dose. The finding was further supported by safety information from four patients under 2 years of age who were treated in the study, along with safety data from older pediatric patients. This evidence supported extending the indication to the youngest patients while maintaining the evidentiary standards required for approval.</p>
<h3 style="user-select: auto !important;"><strong style="user-select: auto !important;">Safety Profile and FDA Designations</strong></h3>
<p style="user-select: auto !important;">The most common side effects associated with Zanvastro include vomiting, back pain, cough, headache, and post-lumbar puncture syndrome. Patients and caregivers have been advised to notify their healthcare provider if symptoms consistent with meningitis occur, as aseptic meningitis has been reported among patients treated with Zanvastro. Patients and healthcare providers should carefully review the full prescribing information when considering treatment decisions.</p>
<p style="user-select: auto !important;">Zanvastro received Orphan Drug, Fast Track, Breakthrough Therapy, and Rare Pediatric Disease and Priority Review Voucher designations. These designations reflect the serious and rare nature of Alexander disease and FDA’s commitment to rare disease drug development. The approval of Zanvastro for the treatment of Alexander disease was granted to Ionis Pharmaceuticals, Inc.</p>The post <a href="https://www.pharmaadvancement.com/pharma-news/fda-approves-zanvastro-as-first-alexander-disease-treatment/">FDA Approves Zanvastro as First Alexander Disease Treatment</a> appeared first on <a href="https://www.pharmaadvancement.com">Pharma Advancement</a>.]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>FDA Approves Mimrylo for Rare Blood Disorder Treatment</title>
		<link>https://www.pharmaadvancement.com/pharma-news/fda-approves-mimrylo-for-rare-blood-disorder-treatment/</link>
		
		<dc:creator><![CDATA[API PA]]></dc:creator>
		<pubDate>Mon, 31 Aug 2026 07:54:31 +0000</pubDate>
				<category><![CDATA[FDA Approvals]]></category>
		<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.pharmaadvancement.com/uncategorised/fda-approves-mimrylo-for-rare-blood-disorder-treatment/</guid>

					<description><![CDATA[<p>The U.S. Food and Drug Administration (FDA) approved Mimrylo (rusfertide), a new treatment for adults with polycythemia vera, a rare blood disorder in which the body produces excessive amounts of red blood cells. This overproduction can make the blood thicker and raise the likelihood of cardiovascular complications, including blood clots, stroke and heart attack. Mimrylo [&#8230;]</p>
The post <a href="https://www.pharmaadvancement.com/pharma-news/fda-approves-mimrylo-for-rare-blood-disorder-treatment/">FDA Approves Mimrylo for Rare Blood Disorder Treatment</a> appeared first on <a href="https://www.pharmaadvancement.com">Pharma Advancement</a>.]]></description>
										<content:encoded><![CDATA[<p style="user-select: auto !important;">The U.S. Food and Drug Administration (FDA) approved Mimrylo (rusfertide), a new treatment for adults with polycythemia vera, a rare blood disorder in which the body produces excessive amounts of red blood cells. This overproduction can make the blood thicker and raise the likelihood of cardiovascular complications, including blood clots, stroke and heart attack.</p>
<p style="user-select: auto !important;">Mimrylo provides a new treatment approach for patients whose polycythemia vera has not been adequately controlled through existing therapies. The medicine is the first approved treatment for polycythemia vera designed to mimic hepcidin, a hormone that naturally regulates iron in the body. By restricting the amount of iron available for producing new red blood cells, Mimrylo is intended to reduce their overproduction and help maintain red blood cell levels under control. The treatment therefore gives patients whose disease remains inadequately controlled with existing therapies another option.</p>
<p style="user-select: auto !important;">&#8220;People living with polycythemia vera have long faced the challenge of managing a chronic blood disorder with frequent blood draws to help address the consequences of the red blood cell overproduction,&#8221; said Tanya Wroblewski, M.D., Director of the Division of Nonmalignant Hematology within the FDA’s Center for Drug Evaluation and Research.</p>
<p style="user-select: auto !important;">&#8220;Today&#8217;s approval of Mimrylo offers a new, first-in-class option that has the potential to meaningfully reduce patient burden,&#8221; she added.</p>
<p style="user-select: auto !important;">A central objective in treating polycythemia vera is maintaining the proportion of red blood cells in the blood, known as hematocrit, below 45% in order to lower cardiovascular risks. Phlebotomy is frequently used to achieve this goal. The procedure removes blood from a vein to reduce the number of red blood cells in the body. For some patients, however, treatment does not prevent the need for repeated phlebotomies, leaving them with an ongoing treatment burden associated with the rare blood disorder.</p>
<h3 style="user-select: auto !important;"><strong style="user-select: auto !important;">VERIFY Trial Evaluates Safety and Efficacy</strong></h3>
<h4 style="user-select: auto !important;"><strong style="user-select: auto !important;">Phase 3 Study Shows Reduced Need for Phlebotomy</strong></h4>
<p style="user-select: auto !important;">The safety and efficacy of Mimrylo were assessed through the VERIFY trial, a multicenter, randomized, double-blind, placebo-controlled phase 3 study involving 293 adults with polycythemia vera. Participants in the trial required frequent phlebotomies despite continuing standard-of-care therapy. They were randomized 1:1 to receive either Mimrylo or placebo over a 32-week period. Treatment with Mimrylo began at 19 mg and was administered subcutaneously (under the skin) once weekly. The dose was then titrated with the objective of maintaining hematocrit levels below 45%.</p>
<p style="user-select: auto !important;">The trial measured efficacy according to the proportion of patients who did not meet the criteria for phlebotomy between weeks 20 and 32 of the study. During the 32-week period, 76.9% of patients receiving Mimrylo did not require any phlebotomies, compared with 32.9% of patients who received placebo. The most common adverse reactions reported with Mimrylo were injection site reactions and anemia.</p>
<p style="user-select: auto !important;">Mimrylo received priority review, with the approval granted to Takeda Pharmaceuticals America, Inc.</p>The post <a href="https://www.pharmaadvancement.com/pharma-news/fda-approves-mimrylo-for-rare-blood-disorder-treatment/">FDA Approves Mimrylo for Rare Blood Disorder Treatment</a> appeared first on <a href="https://www.pharmaadvancement.com">Pharma Advancement</a>.]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>FDA Approves Rasonque for Metastatic Pancreatic Cancer</title>
		<link>https://www.pharmaadvancement.com/pharma-news/fda-approves-rasonque-for-metastatic-pancreatic-cancer/</link>
		
		<dc:creator><![CDATA[API PA]]></dc:creator>
		<pubDate>Thu, 27 Aug 2026 09:54:42 +0000</pubDate>
				<category><![CDATA[FDA Approvals]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Research & Development]]></category>
		<guid isPermaLink="false">https://www.pharmaadvancement.com/uncategorised/fda-approves-rasonque-for-metastatic-pancreatic-cancer/</guid>

					<description><![CDATA[<p>The U.S. Food and Drug Administration (FDA) has approved Rasonque (daraxonrasib), a RAS inhibitor designed for the most common form of pancreatic cancer. The decision introduces a new treatment option for patients with advanced pancreatic cancer and comes months ahead of schedule. The agency said the action reflects its commitment to acting with urgency, limiting [&#8230;]</p>
The post <a href="https://www.pharmaadvancement.com/pharma-news/fda-approves-rasonque-for-metastatic-pancreatic-cancer/">FDA Approves Rasonque for Metastatic Pancreatic Cancer</a> appeared first on <a href="https://www.pharmaadvancement.com">Pharma Advancement</a>.]]></description>
										<content:encoded><![CDATA[<p style="user-select: auto !important;">The U.S. Food and Drug Administration (FDA) has approved Rasonque (daraxonrasib), a RAS inhibitor designed for the most common form of pancreatic cancer. The decision introduces a new treatment option for patients with advanced pancreatic cancer and comes months ahead of schedule. The agency said the action reflects its commitment to acting with urgency, limiting unnecessary delays and supporting the development of innovative treatments that can make a meaningful difference for American patients and their families. The FDA granted the approval to Revolution Medicines, Inc.</p>
<p style="user-select: auto !important;">Rasonque is administered as a tablet once daily and works by targeting multiple forms of a protein called RAS. The protein is a key driver of tumor growth in most patients with pancreatic adenocarcinoma, a cancer that develops from cells lining the ducts of the pancreas. The approval covers adults with metastatic pancreatic cancer in the form of pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.</p>
<p style="user-select: auto !important;">&#8220;Today’s approval provides a critical new option for patients facing an extraordinarily difficult and historically hard-to-treat cancer. It is our fundamental duty to deliver more cures and meaningful treatments to patients as quickly as possible,&#8221; said Acting FDA Commissioner Kyle Diamantas, J.D.</p>
<p style="user-select: auto !important;">&#8220;I am immensely proud of the dedicated FDA scientists whose fast, thorough review and relentless commitment made this groundbreaking milestone a reality,&#8221; he added.</p>
<h3 style="user-select: auto !important;"><strong style="user-select: auto !important;">Clinical Trial Shows Survival Benefit</strong></h3>
<p style="user-select: auto !important;">Pancreatic adenocarcinoma represents approximately 90% to 95% of the 67,000 new cases of pancreatic cancer diagnosed in the United States each year, according to the National Cancer Institute. Although pancreatic adenocarcinoma makes up roughly 3.2% of all cancer diagnoses, it contributes a disproportionately high share of cancer deaths. The source attributes that burden to the disease’s typically late detection, aggressive course and historically limited treatment options.</p>
<p style="user-select: auto !important;">Evidence supporting Rasonque came from a randomized, open-label, multicenter clinical trial involving 500 adults with previously treated metastatic pancreatic adenocarcinoma. In the study, Rasonque increased median overall survival to 13.2 months, compared with 6.7 months for standard chemotherapy.</p>
<p style="user-select: auto !important;">&#8220;This drug showed unprecedented results in an area of high unmet need,&#8221; said Angelo de Claro, M.D., director of the FDA’s Oncology Center of Excellence.</p>
<p style="user-select: auto !important;">&#8220;The approval was granted 6.5 months before the user fee deadline, demonstrating the FDA’s commitment to accelerating the approval of new cancer treatments for patients with serious and life-threatening conditions,&#8221; he added.</p>
<h3 style="user-select: auto !important;"><strong style="user-select: auto !important;">Rasonque Receives Multiple FDA Designations</strong></h3>
<p style="user-select: auto !important;">The FDA granted Rasonque Breakthrough Therapy and Orphan Drug designations, while the treatment also received Priority Review for this indication. The application underwent an additional review through the Commissioner’s National Priority Voucher pilot program, which is intended to accelerate the review of therapies addressing national public health priorities.</p>
<p style="user-select: auto !important;">In May 2026, the FDA issued a “safe to proceed” letter allowing the sponsor to begin an expanded access treatment protocol for Rasonque. This enabled patient access to the investigational drug before approval under applicable FDA regulations.</p>The post <a href="https://www.pharmaadvancement.com/pharma-news/fda-approves-rasonque-for-metastatic-pancreatic-cancer/">FDA Approves Rasonque for Metastatic Pancreatic Cancer</a> appeared first on <a href="https://www.pharmaadvancement.com">Pharma Advancement</a>.]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Sourcing High-Quality Magnesium Glycinate: How Supplement Manufacturers Can Verify a Truly Chelated Ingredient</title>
		<link>https://www.pharmaadvancement.com/pharma-news/sourcing-high-quality-magnesium-glycinate-how-supplement-manufacturers-can-verify-a-truly-chelated-ingredient/</link>
		
		<dc:creator><![CDATA[API PA]]></dc:creator>
		<pubDate>Mon, 24 Aug 2026 13:10:04 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.pharmaadvancement.com/uncategorised/sourcing-high-quality-magnesium-glycinate-how-supplement-manufacturers-can-verify-a-truly-chelated-ingredient/</guid>

					<description><![CDATA[<p>As magnesium glycinate expands across dietary supplements, sports nutrition, sleep-support products, and functional foods and beverages, manufacturers have no shortage of suppliers. The harder question is how to identify a high-purity, fully reacted, truly chelated magnesium glycinate—and avoid lower-cost materials containing other magnesium forms or incomplete chelation. Products sold as magnesium glycinate or magnesium bisglycinate [&#8230;]</p>
The post <a href="https://www.pharmaadvancement.com/pharma-news/sourcing-high-quality-magnesium-glycinate-how-supplement-manufacturers-can-verify-a-truly-chelated-ingredient/">Sourcing High-Quality Magnesium Glycinate: How Supplement Manufacturers Can Verify a Truly Chelated Ingredient</a> appeared first on <a href="https://www.pharmaadvancement.com">Pharma Advancement</a>.]]></description>
										<content:encoded><![CDATA[<p>As magnesium glycinate expands across dietary supplements, sports nutrition, sleep-support products, and functional foods and beverages, manufacturers have no shortage of suppliers.</p>
<p>The harder question is how to identify a <strong>high-purity, fully reacted, truly chelated magnesium glycinate</strong>—and avoid lower-cost materials containing other magnesium forms or incomplete chelation.</p>
<p>Products sold as magnesium glycinate or magnesium bisglycinate can differ significantly in composition and quality. Some are fully reacted, unbuffered magnesium glycinate, while others may contain magnesium oxide or other magnesium salts. Two products carrying the same ingredient name are therefore not necessarily equivalent raw materials.</p>
<h3><strong>The True Cost of a Lower-Cost Ingredient</strong></h3>
<p>Price per kilogram matters, but only when the materials being compared are genuinely comparable.</p>
<p>Differences in composition, chelation, or sensory performance can lead to reformulation, additional QA work, repeated testing, and supplier requalification. A lower ingredient price can quickly lose its advantage if it creates downstream formulation or production costs.</p>
<p>The better sourcing question is not simply, “Which magnesium glycinate is cheapest?” but:</p>
<p><strong>Which supplier offers the strongest value after purity, chelation, formulation performance, and commercial supply are verified?</strong></p>
<h3><strong>12% Elemental Magnesium Does Not Automatically Mean High-Purity Magnesium Glycinate</strong></h3>
<p>Elemental magnesium percentage affects serving size and dosage-form design, but it does not establish <strong>what chemical form that magnesium is in</strong>.</p>
<p>A higher elemental magnesium result does not automatically prove higher magnesium bisglycinate purity or complete chelation. Magnesium oxide or another magnesium source can also increase elemental magnesium.</p>
<p>When <a href="https://www.magneinno.com/blog/how-to-choose-a-magnesium-glycinate-supplier-for-u-s-supplement-brands" target="_blank" rel="noopener">evaluating a magnesium glycinate supplier</a>, procurement and QA teams should therefore review evidence supporting ingredient identity, purity, chelation status, and free magnesium—not elemental magnesium alone.</p>
<h3><strong>Ask Suppliers to Prove What You Are Buying</strong></h3>
<p><img fetchpriority="high" decoding="async" class="aligncenter wp-image-37872 size-large" src="https://www.pharmaadvancement.com/wp-content/uploads/2026/08/6ee30f8b-f9cf-451c-81d9-62420197eb83-1024x768-1.jpeg" alt="" width="696" height="522" /></p>
<p><a href="https://www.magneinno.com/contact" target="_blank" rel="noopener">MagneINNO</a> is a B2B magnesium glycinate ingredient brand serving dietary supplement, sports nutrition, and functional-product manufacturers with high-purity, fully chelated, unbuffered magnesium glycinate / magnesium bisglycinate.</p>
<p>Its magnesium bisglycinate purity can reach <strong>99.8%</strong>. A <strong>seven-method analytical verification system</strong> evaluates identity and chelation from multiple perspectives. For the 12% magnesium grade, elemental magnesium is verified by <strong>ICP-OES</strong>, while <strong>Free Mg is specified at ≤0.02% w/w</strong>.</p>
<p>A proprietary chelation process and patented verification technology provide additional support for verifying a fully chelated ingredient rather than relying on elemental magnesium alone.</p>
<h3><strong>Match the Grade to the Dosage Form</strong></h3>
<p>MagneINNO offers three application-oriented grades:</p>
<ul>
<li><strong>12% Magnesium – Taste Optimized:</strong> for capsules and tablets.</li>
<li><strong>10% Magnesium – Taste Free:</strong> for powders and stick packs.</li>
<li><strong>8% Magnesium – Ultra Taste Free:</strong> for gummies and beverages.</li>
</ul>
<p>This allows formulation teams to select magnesium glycinate around the finished dosage form rather than force one specification into every application.</p>
<h3><strong>Verify Quality and Commercial Supply</strong></h3>
<p>Commercial qualification requires more than a successful sample. Manufacturers also need specifications, COAs, quality documentation, reliable capacity, and inventory.</p>
<p>MagneINNO&#8217;s quality and compliance platform includes <strong>GRAS, GMP/cGMP, NSF Certified for Sport, FDA facility registration, ISO, FSSC, Non-GMO, Halal, and Kosher</strong> support. Research and clinical programs also cover key magnesium glycinate applications including <strong>sleep quality and exercise recovery</strong>.</p>
<p>For commercial supply, MagneINNO supports <strong>3,000+ metric tons of annual production capacity</strong>, a <strong>50,000 sq ft California warehouse</strong>, and <strong>dozens of metric tons of U.S.-positioned inventory</strong>.</p>
<p>For brands that already have an incumbent supplier, qualifying MagneINNO as a second source can reduce dependence on a single supply channel and provide greater flexibility when lead times, inventory, or demand change.</p>
<h3><strong>Meet MagneINNO at SupplySide Global 2026</strong></h3>
<p><img decoding="async" class="aligncenter wp-image-37874 size-large" src="https://www.pharmaadvancement.com/wp-content/uploads/2026/08/4f08274a-76cd-41d4-93e3-37943c00326a-1024x1024-1.jpeg" alt="" width="696" height="696" /></p>
<p>MagneINNO will exhibit at <strong>SupplySide Global 2026, October 28–30 at Mandalay Bay in Las Vegas, Booth #6145</strong>.</p>
<p>On <strong>October 28 from 3:00–5:00 PM</strong>, MagneINNO will host a booth reception with champagne and cake. Procurement, QA, R&amp;D, and product-development teams are invited to discuss specifications, COAs, chelation verification, samples, formulation requirements, and commercial supply.</p>
<h3><strong>About MagneINNO</strong></h3>
<p><strong>MagneINNO is a B2B ingredient brand focused exclusively on high-purity, fully chelated magnesium glycinate / magnesium bisglycinate for dietary supplement, sports nutrition, functional beverage, and wellness-product manufacturers.</strong></p>
<p>Its core platform is <strong>fully chelated, fully reacted, unbuffered magnesium glycinate</strong>, rather than buffered blends containing added magnesium oxide or other magnesium salts.</p>
<p>MagneINNO magnesium bisglycinate can achieve <strong>99.8% purity</strong>, supported by a <strong>proprietary chelation process, seven-method analytical verification system, patented verification technology, ICP-OES elemental magnesium verification, and Free Mg ≤0.02% w/w</strong> for its 12% grade.</p>
<p>The portfolio includes <strong>12% Magnesium – Taste Optimized for capsules and tablets, 10% Magnesium – Taste Free for powders and stick packs, and 8% Magnesium – Ultra Taste Free for gummies and beverages</strong>.</p>
<p>Quality and compliance support includes <strong>GRAS, GMP/cGMP, NSF Certified for Sport, FDA facility registration, ISO, FSSC, Non-GMO, Halal, and Kosher</strong>, while research and clinical programs cover <strong>sleep quality and exercise recovery</strong>.</p>
<p>Commercially, MagneINNO combines <strong>3,000+ metric tons/year of production capacity</strong> with a <strong>50,000 sq ft California warehouse</strong> and <strong>dozens of metric tons of ready-to-ship U.S. inventory</strong>. Commercial material is available in <strong>25 kg drums</strong> with a <strong>24-month shelf life</strong>, and <strong>50 g samples, specifications, COAs, and supplier-qualification documentation</strong> are available for evaluation.</p>
<p>Manufacturers can qualify MagneINNO as either a <strong>primary magnesium glycinate source or a second source</strong> before moving into commercial purchasing.</p>The post <a href="https://www.pharmaadvancement.com/pharma-news/sourcing-high-quality-magnesium-glycinate-how-supplement-manufacturers-can-verify-a-truly-chelated-ingredient/">Sourcing High-Quality Magnesium Glycinate: How Supplement Manufacturers Can Verify a Truly Chelated Ingredient</a> appeared first on <a href="https://www.pharmaadvancement.com">Pharma Advancement</a>.]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
